Fishawack Group Acquires Healthcircle to Strengthen Creative Offering
The Fishawack Group of Companies, one of the world’s largest independent medical communications organisations, has acquired Healthcircle Advertising Limited, a strategic brand communications agency with offices in London and Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005905/en/
Top row: Dominic Miller, Fishawack COO, Gail Flockhart, Fishawack Managing Partner, Liz Maclaren, Healthcircle Creative Director, Dr. David Ingram, Healthcircle Managing Partner; Bottom row: Mike Taylor, Healthcircle Managing Director, Oliver Dennis, Fishawack CEO (Photo: Business Wire)
“This acquisition is a major step in Fishawack’s plan to build a global strategic creative agency that can work alongside our medical communications business,” explained Oliver Dennis, Chief Executive Officer of the Fishawack Group. “We also acquired US-based Carling Communications in July last year. Carling needed critical mass in Europe and Healthcircle needed a US partner. This is a great match and positions us to deliver integrated creative and medcomms solutions for clients on a truly global scale.”
Mike Taylor, Managing Director of Healthcircle added, “We’ve been on the lookout for a partner to support our growth in the US whilst also providing us access to scientific and strategic talent. Healthcircle and Fishawack have already collaborated extensively and we’ve known and worked with many of the Carling team over our years in the business.”
Gail Flockhart, Group Managing Director at Fishawack said, “All agencies are collections of people with different talents. What makes us different is the investment we make in establishing real chemistry between teams so that collaboration is fun and triggers new ideas. We’re still at a size where we can make this meaningful.”
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications specialists, with offices in the UK (Knutsford, Oxford, and Brighton), the USA (Philadelphia, PA, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
For over 17 years, Fishawack has been partnering with global and regional pharmaceutical, biotechnology, and medical device clients to develop and deliver services in the fields of medical communications, scientific engagement, market access, strategic consultancy, and thought leader consultancy. For more detailed information about our services, please see the Fishawack Group website at www.fishawack.com.
We have built our reputation on excellence, creativity, and transparency.
About Healthcircle
Healthcircle is a full-service strategic brand communications agency. With extensive experience in direct-to-patient communications, creative digital solutions and creative medcomms, Healthcircle has consistently won awards for its surprising and innovative creative work. Healthcircle is headquartered in London, UK, with an office in Cascais, Portugal.
Healthcircle strongly believes that connecting strategy and creative is the key to brand success and has demonstrated the success of this approach on some of the largest brands in the global pharmaceutical marketplace during the last 10 years. More information is available at www.healthcircle-uk.com
Fishawack Group of Companies
www.fishawack.com
Twitter:
@Fishawack
LinkedIn:
Fishawack Group of Companies
Headquarters:
100–102 King Street, Knutsford, Cheshire, WA16 6HQ, UK
Tel: +44
1565 756600
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005905/en/
Contact information
The Fishawack Group
Gail Flockhart
Group
Managing Director
gail.flockhart@fishawack.com
or
Healthcircle
Advertising Ltd
Mike Taylor
Managing Director
Mike.taylor@Healthcircle-uk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom